Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
05 February 2021Website:
http://www.boltbio.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 22:06:24 GMTDividend
Analysts recommendations
Institutional Ownership
BOLT Latest News
NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. (“Bolt” or the “Company”) (NASDAQ: BOLT) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv-03985, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Bolt securities between February 5, 2021 and May 14, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK , July 6, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
NEW YORK , July 3, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt securities between February 5, 2021, and May 14, 2024, inclusive (the "Class Period").
SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) securities between February 5, 2021 and May 14, 2024. Bolt, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.
NEW YORK--(BUSINESS WIRE)---- $BOLT #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. (“Bolt” or “the Company”) (NASDAQ: BOLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Bolt s.
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. (“Bolt” or “the Company”) (NASDAQ: BOLT) and certain of its officers.
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased securities of Bolt Biotherapeutics, Inc. (“Bolt” or the “Company”) (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, inclusive (the “Class Period”).
ATLANTA, July 03, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against officers of Bolt Biotherapeutics, Inc. (“Bolt” or the “Company”) (NASDAQ: BOLT). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information, regarding the Company's business, operations, and prospects, including allegations that: (i) Bolt's product, BDC-1001, was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria; (ii) accordingly, Defendants overstated the clinical and/or commercial prospects of Bolt's product pipeline, on which the Company primarily relies to sustain its business model; and (iii) all of the foregoing subjected Bolt to a heightened risk of disruptive leadership transitions and substantial workforce reduction.
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv-03985, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Bolt securities between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- 1(current)
What type of business is Bolt Biotherapeutics?
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
What sector is Bolt Biotherapeutics in?
Bolt Biotherapeutics is in the Healthcare sector
What industry is Bolt Biotherapeutics in?
Bolt Biotherapeutics is in the Biotechnology industry
What country is Bolt Biotherapeutics from?
Bolt Biotherapeutics is headquartered in United States
When did Bolt Biotherapeutics go public?
Bolt Biotherapeutics initial public offering (IPO) was on 05 February 2021
What is Bolt Biotherapeutics website?
https://www.boltbio.com
Is Bolt Biotherapeutics in the S&P 500?
No, Bolt Biotherapeutics is not included in the S&P 500 index
Is Bolt Biotherapeutics in the NASDAQ 100?
No, Bolt Biotherapeutics is not included in the NASDAQ 100 index
Is Bolt Biotherapeutics in the Dow Jones?
No, Bolt Biotherapeutics is not included in the Dow Jones index
When does Bolt Biotherapeutics report earnings?
The next expected earnings date for Bolt Biotherapeutics is 07 August 2024